Articles Accepted

PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
by Dr. Phool , 02 Oct 2023
Co-Author(s): Himanshu Sharma

The fear that people's cognitive capacities would decline with aging is one of the most frequently voiced concerns. This greatly affects daily living and is especially noticeable in patients with neurodegenerative and mental diseases like AD, schizophrenia, and depression. The present study sought to elucidate the adverse effects of PDE-Is on perception, feasible underlying mechanisms, and their application to existing hypotheses regarding the formation of memories. The review encompasses the body of literature from 2010 to 2023. Information was gathered from a range of sources, including books, theses, journals, and electronic searches on the Internet with databases. The brain processes information more quickly, concentrates, remembers things, and uses executive function and memory when PDE inhibitors are present. The most likely contenders and hopeful options for enhancing cognition are PDE2-Is or PDE9-Is. Realizing PDE-Is' potential as cognitive relishes will need the creation of isoform-specific PDE-Is with a minimum of negative properties.

Current Issue
May 2024
Quick Contact